4′-Hydroxyglibenclamide, with the CAS number 23155-04-6, is a derivative of glibenclamide, which is an antidiabetic medication used primarily in the management of type 2 diabetes. This compound features a hydroxy group at the para position of the phenyl ring, which alters its pharmacological properties compared to its parent compound. It is characterized by its ability to stimulate insulin secretion from pancreatic beta cells, thereby lowering blood glucose levels. The molecular structure includes a sulfonylurea moiety, which is essential for its biological activity. 4′-Hydroxyglibenclamide is typically a white to off-white crystalline powder, and it is soluble in organic solvents but has limited solubility in water. Its pharmacokinetics may differ from glibenclamide, affecting its efficacy and safety profile. As with other sulfonylureas, it may cause side effects such as hypoglycemia and weight gain, necessitating careful monitoring in patients. Overall, this compound represents an important aspect of diabetes pharmacotherapy, contributing to the diverse strategies for glycemic control.

4′-Hydroxyglibenclamide

23155-04-6: , Urea, 1-[[p-[2-(5-chloro-o-anisamido)ethyl]phenyl]sulfonyl]-3-(4-hydroxycyclohexyl)-, Benzamide, 5-chloro-N-[2-[4-[[[[(4-hydroxycyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy-, 5-Chloro-N-[2-[4-[[[[(4-hydroxycyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxybenzamide, 4′-Hydroxyglibenclamide

CAS 23155-04-6: 4′-Hydroxyglibenclamide

Benzamide, 5-chloro-N-[2-[4-[[[[(4-hydroxycyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy-

Ref: IN-DA002MES

rac trans-4-Hydroxy Glyburide

Ref: 4Z-G-135